Zosano Pharma (ZSAN) Reaches $16.99 After 5.00% Up Move; Cullen Capital Management Decreased Its Astrazeneca Plc (Adr) (AZN) Position

March 13, 2018 - By Marguerite Chambers

Cullen Capital Management Llc decreased Astrazeneca Plc (Adr) (AZN) stake by 1.21% reported in 2017Q3 SEC filing. Cullen Capital Management Llc sold 21,670 shares as Astrazeneca Plc (Adr) (AZN)’s stock rose 16.26%. The Cullen Capital Management Llc holds 1.76 million shares with $59.74 million value, down from 1.78M last quarter. Astrazeneca Plc (Adr) now has $85.01B valuation. The stock increased 0.47% or $0.16 during the last trading session, reaching $34.01. About 1.29M shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since March 13, 2017 and is uptrending. It has outperformed by 2.75% the S&P500.

The stock of Zosano Pharma Corporation (NASDAQ:ZSAN) is a huge mover today! The stock increased 10.40% or $1.6 during the last trading session, reaching $16.99. About 967,380 shares traded. Zosano Pharma Corporation (NASDAQ:ZSAN) has declined 31.28% since March 13, 2017 and is downtrending. It has underperformed by 47.98% the S&P500.The move comes after 7 months positive chart setup for the $33.52 million company. It was reported on Mar, 13 by Barchart.com. We have $17.84 PT which if reached, will make NASDAQ:ZSAN worth $1.68M more.

Cullen Capital Management Llc increased Pfizer Inc. (NYSE:PFE) stake by 83,441 shares to 1.88M valued at $67.25M in 2017Q3. It also upped Hcp Inc. (NYSE:HCP) stake by 25,630 shares and now owns 1.09 million shares. Merck & Co. Inc. (NYSE:MRK) was raised too.

Among 26 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 16 have Buy rating, 0 Sell and 10 Hold. Therefore 62% are positive. AstraZeneca plc (ADR) had 44 analyst reports since July 31, 2015 according to SRatingsIntel. Jefferies downgraded the shares of AZN in report on Monday, April 10 to “Hold” rating. The rating was downgraded by Jefferies on Tuesday, March 15 to “Hold”. The stock of AstraZeneca PLC (NYSE:AZN) has “Buy” rating given on Friday, July 31 by S&P Research. The rating was upgraded by Leerink Swann on Friday, December 9 to “Outperform”. The firm has “Top Pick” rating by Oddo & Cie given on Tuesday, January 26. Liberum Capital downgraded AstraZeneca PLC (NYSE:AZN) on Thursday, September 14 to “Hold” rating. The company was upgraded on Monday, September 14 by Deutsche Bank. Argus Research upgraded the shares of AZN in report on Monday, August 29 to “Buy” rating. The firm has “Market Perform” rating given on Tuesday, February 6 by Leerink Swann. As per Thursday, July 27, the company rating was downgraded by Leerink Swann.

Analysts await AstraZeneca PLC (NYSE:AZN) to report earnings on April, 26. They expect $0.44 earnings per share, down 55.56% or $0.55 from last year’s $0.99 per share. AZN’s profit will be $1.10 billion for 19.32 P/E if the $0.44 EPS becomes a reality. After $1.30 actual earnings per share reported by AstraZeneca PLC for the previous quarter, Wall Street now forecasts -66.15% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts